iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Boston, Massachusetts--(Newsfile Corp. - February 3, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of iRhythm Technologies, Inc. (NASDAQ: IRTC). The case is currently in the lead plaintiff stage. Investors who purchased IRTC stock or other securities between August 4, 2020 and January 28, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/iRhythm to submit their information. Investors may also...

iRhythm Investor Alert: Shareholder Lawsuit Filed

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC) in the United States District Court for the Northern District of California on behalf of those who purchased or acquired the securities of iRhythm between August 4, 2020 and January 28, 2021, inclusive (the “Class Period”). The lawsuit seeks to recover damages for iRhythm investors under the federal securities laws.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against iRhythm Technologies, Inc. (IRTC)

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow LLP, a nationally ranked and award-winning investor rights law firm, announces it is developing a proprietary investigation concerning potential securities fraud claims on behalf of shareholders of iRhythm Technologies Inc. (NASDAQ: IRTC) resulting from allegations that iRhythm may have issued materially misleading business information to the investing public. iRhythm Technologies provides wearable biosensor devices to detect and monitor heart arrythm

IRTC ALERT: iRhythm (NASDAQ: IRTC) Drops Significantly On Slash in Medicare Reimbursement Rates For Key Products; Labaton Sucharow Announces Investigation of iRhythm Technologies, Inc. and Strongly Encourages Investors With Losses to Contact the Firm

NEW YORK, Feb. 2, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of iRhythm Technologies, Inc. (NASDAQ: IRTC) between August 4, 2020 and January 28, 2021, inclusive (the...

BREAKING ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages iRhythm Technologies, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline - IRTC

PHILADELPHIA, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of iRhythm Technologies, Inc. (“iRhythm” or the “Company”) ( NASDAQ: IRTC ) to determine whether the Company engaged in securities fraud or other unlawful business practices.

Have You Invested In iRhythm And Suffered Losses Greater Than $100,000 – Kehoe Law Firm, P.C. Class Action Investigation On Behalf Of IRTC Investors

STOCK ALERT: iRhythm Drops Significantly On Slash in Medicare Reimbursement Rates For Key Products; Labaton Sucharow Announces Investigation of iRhythm Technologies, Inc. and Strongly Encourages Investors With Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased iRhythm Technologies, Inc. (NASDAQ: IRTC) common stock between August 4, 2020 and January 28, 2021 (the “Class Period”). Investors have until April 2, 2021 to apply to the Court to be appointed as lead plaintiff in the

IRHYTHM ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against iRhythm Technologies, Inc. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of iRhythm Technologies, Inc. (NASDAQ: IRTC) between August 4, 2020 and January 28, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 2, 2021. SO WHAT: If you purchased iRhythm securities during the Class Per

Breaking News: Rosen Law Firm Encourages iRhythm Technologies, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – IRTC

SAN DIEGO, Jan. 31, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by iRhythm Technologies, Inc. ("iRhythm" or the "Company") (NASDAQ: IRTC). iRhythm stock suffered a steep decline following the...

(IRTC) iRhythm Investigation Alert: Did You Lose Money on Your Investment? Contact Johnson Fistel Regarding Investigation

Atlanta, Georgia--(Newsfile Corp. - January 29, 2021) - Holzer & Holzer, LLC is investigating whether iRhythm Technologies, Inc. ("iRhythm" or the "Company") (NASDAQ: IRTC) complied with federal securities laws. On January 29, 2021, a Baird research analyst indicated that Novartis, a Medicare Administrative Contractor, reimbursement rates concerning heart monitors are "way lower than" those published in the Medicare Physician Fee Schedule. The price of iRhythm's stock fell following the announcement.If you purchased shares of...

SHAREHOLDER ALERT: Investigation of iRhythm Announced by Holzer & Holzer, LLC

SAN FRANCISCO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, commented on the recent publication by Novitas Solutions (“Novitas”) of rates applicable to the Current Procedural Terminology (CPT) codes 93241, 93243, 93245 and 93247.

iRhythm Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas Recent Rate Publication

Investors are heartened by the cardiac device maker's revenue growth.

Why iRhythm Technologies Stock Skyrocketed 248% in 2020

AdaptHealth Corp

Retractable Technologies

Sanara MedTech Inc.

Zai Lab Ltd.

These companies made millions by developing equipment for life-saving care, and enriched shareholders too.

These Were the 5 Best Medical Device Stocks of 2020

SAN FRANCISCO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference.

iRhythm Technologies to Present at the 39th Annual J.P. Morgan Healthcare Conference

Nuance Communications

Invitae

Teladoc

The rapid adoption of telemedicine and digital health during COVID-19 pandemic is remarkable, yet unsurprising. In the years preceding the health crisis we now find ourselves in, a paradigm shift in health care toward digitization was percolating.

4 Companies At The Center Of The Telemedicine And Digital Health Revolution

SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that Kevin King will retire as President and CEO effective January 12, 2021. Mr. King will continue to serve on iRhythm's board of directors and as an advisor to the business. Effective the same date, Mike Coyle will join the company as President and CEO and as a member of its board of directors.

iRhythm Technologies President and CEO Kevin King to Retire; Michael Coyle Joins Company as President and CEO Effective January 12, 2021

Investors didn't like what they saw in new Medicare guidelines.

Why iRhythm Technologies Stock Is Tanking Today

Webcast Scheduled for December 2, 2020 at 5:30 am PT/8:30 am ET Webcast Scheduled for December 2, 2020 at 5:30 am PT/8:30 am ET

iRhythm Technologies Comments on Centers for Medicare and Medicaid Services 2021 Medicare Physician Fee Schedule Final Rule

Remote cardiac monitoring service Zio XT has been evaluated and positively recommended by NICE Remote cardiac monitoring service Zio XT has been evaluated and positively recommended by NICE

iRhythm Technologies Receives Positive National Guidance in First of its Kind Digital Health Pilot with National Institute for Health and Care Excellence

Match Group

Snowflake

Sands Capital Management recently disclosed its portfolio updates for the third quarter of 2020, which ended on Sept. 30.

Top 3rd-Quarter Buys of Frank Sands' Firm

SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study.

Zio by iRhythm Detects Previously Undiagnosed Atrial Fibrillation and Helps to Prevent Hospitalizations, Stroke, and Death as a Result

American Well Corporation

Castlight Health

Global X Telemedicine & Digital Health ETF

GoodRx Holdings

Humana

Telehealth stocks have come to prominence in 2020 for obvious reasons. Read on for those that are positioned to thrive moving forward.

7 Telehealth Stocks To Buy Ahead Of Flu Season

iRhythm to Host Webcast to Discuss Outcomes on Monday, November 16, 2020 iRhythm to Host Webcast to Discuss Outcomes on Monday, November 16, 2020

iRhythm Technologies Announces Data from mSToPS Clinical Trial to be Presented in a Late-Breaking Scientific Session at American Heart Association 2020

M3 Inc

There are no silver linings to the pandemic. Nevertheless, some stocks and sectors have benefited greatly from the societal changes COVID-19 has wrought.

5 Telehealth Stocks for Long-Term Financial Fitness

iRhythm Technologies, Inc. (IRTC) CEO Kevin King on Q3 2020 Results - Earnings Call Transcript

News for iRhythm Technologies Stock (IRTC)